B3GALT1

Summary

B3GALT1 (beta-1,3-galactosyltransferase 1, HGNC:916) is a protein-coding gene on chromosome 2q24.3, encoding Beta-1,3-galactosyltransferase 1 (Q9Y5Z6). Beta-1,3-galactosyltransferase that transfers galactose from UDP-alpha-D-galactose to substrates with a terminal beta-N-acetylglucosamine (beta-GlcNAc) residue.

This gene is a member of the beta-1,3-galactosyltransferase (beta3GalT) gene family. This family encodes type II membrane-bound glycoproteins with diverse enzymatic functions using different donor substrates (UDP-galactose and UDP-N-acetylglucosamine) and different acceptor sugars (N-acetylglucosamine, galactose, N-acetylgalactosamine). The beta3GalT genes are distantly related to the Drosophila Brainiac gene and have the protein coding sequence contained in a single exon. The beta3GalT proteins also contain conserved sequences not found in the beta4GalT or alpha3GalT proteins. The carbohydrate chains synthesized by these enzymes are designated as type 1, whereas beta4GalT enzymes synthesize type 2 carbohydrate chains. The ratio of type 1:type 2 chains changes during embryogenesis. By sequence similarity, the beta3GalT genes fall into at least two groups: beta3GalT4 and 4 other beta3GalT genes (beta3GalT1-3, beta3GalT5). This gene is expressed exclusively in the brain. The encoded protein shows strict donor substrate specificity for UDP-galactose.

Source: NCBI Gene 8708 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 47 total — 5 pathogenic, 1 likely-pathogenic
• Druggable target: yes
• MANE Select transcript: NM_020981

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:916
Approved symbol	B3GALT1
Name	beta-1,3-galactosyltransferase 1
Location	2q24.3
Locus type	gene with protein product
Status	Approved
Aliases	beta3Gal-T1
Ensembl gene	ENSG00000172318
Ensembl biotype	protein_coding
OMIM	603093
Entrez	8708

Gene structure

Transcript identifiers

Ensembl transcripts: 2 — 2 protein_coding

ENST00000392690, ENST00000970731

RefSeq mRNA: 1 — MANE Select: NM_020981 NM_020981

CCDS: CCDS2227

Canonical transcript exons

ENST00000392690 — 5 exons

Exon	Start	End
ENSE00001512774	167868811	167874045
ENSE00003929445	167490177	167490277
ENSE00003930584	167646909	167646966
ENSE00003933623	167818672	167818793
ENSE00003934813	167293001	167293334

Expression profiles

Bgee: expression breadth ubiquitous, 136 present calls, max score 85.68.

FANTOM5 (CAGE): breadth broad, TPM avg 3.6884 / max 163.6229, expressed in 568 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
23500	2.9231	521
23501	0.7653	276

Top tissues by expression

244 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	85.68	gold quality
hindlimb stylopod muscle	UBERON:0004252	76.28	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	76.09	gold quality
ganglionic eminence	UBERON:0004023	75.80	gold quality
ventricular zone	UBERON:0003053	74.59	gold quality
gastrocnemius	UBERON:0001388	73.58	gold quality
nucleus accumbens	UBERON:0001882	73.18	gold quality
muscle of leg	UBERON:0001383	73.11	gold quality
Brodmann (1909) area 9	UBERON:0013540	72.88	gold quality
anterior cingulate cortex	UBERON:0009835	72.52	gold quality
prefrontal cortex	UBERON:0000451	72.37	gold quality
rectum	UBERON:0001052	71.79	gold quality
caudate nucleus	UBERON:0001873	71.58	gold quality
putamen	UBERON:0001874	70.97	gold quality
right frontal lobe	UBERON:0002810	70.81	gold quality
amygdala	UBERON:0001876	69.70	gold quality
ileal mucosa	UBERON:0000331	68.89	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	68.14	gold quality
neocortex	UBERON:0001950	67.69	gold quality
tibialis anterior	UBERON:0001385	67.33	silver quality
mucosa of transverse colon	UBERON:0004991	66.67	gold quality
cerebellar cortex	UBERON:0002129	66.48	gold quality
cerebellar hemisphere	UBERON:0002245	66.40	gold quality
frontal cortex	UBERON:0001870	66.39	gold quality
transverse colon	UBERON:0001157	65.79	gold quality
hypothalamus	UBERON:0001898	65.50	gold quality
right hemisphere of cerebellum	UBERON:0014890	65.49	gold quality
cerebellum	UBERON:0002037	64.67	gold quality
cerebral cortex	UBERON:0000956	64.62	gold quality
right uterine tube	UBERON:0001302	64.14	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	74.82
E-GEOD-109979	no	554.92
E-CURD-97	no	45.29
E-ANND-3	no	4.31
E-CURD-112	no	2.41

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

86 targeting B3GALT1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4789-3P	99.99	70.75	2484
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-12133	99.92	71.82	2006
HSA-MIR-10527-5P	99.91	72.28	3754
HSA-MIR-1271-5P	99.91	71.99	1972
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-3140-3P	99.88	68.47	2069
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-5010-3P	99.83	70.60	2357
HSA-MIR-4495	99.82	72.08	3080
HSA-MIR-3133	99.81	70.92	3506
HSA-MIR-323A-3P	99.79	70.30	1739
HSA-MIR-4766-5P	99.75	69.23	2662
HSA-MIR-1255A	99.74	68.09	744
HSA-MIR-1255B-5P	99.74	68.16	741

Literature-anchored findings (GeneRIF, showing 1)

• A new allele with 303 base pairs insertion in B3GALT1 gene identified in an individual with P1 [k] phenotype. (PMID:37283178)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	b3galt1a	ENSDARG00000079700
mus_musculus	B3galt1	ENSMUSG00000034780
rattus_norvegicus	B3galt1	ENSRNOG00000007625
drosophila_melanogaster	brn	FBGN0000221
caenorhabditis_elegans		WBGENE00000270
caenorhabditis_elegans		WBGENE00007096
caenorhabditis_elegans		WBGENE00017653

Paralogs (15): B3GNT7 (ENSG00000156966), B3GALT2 (ENSG00000162630), B3GALNT2 (ENSG00000162885), B3GALNT1 (ENSG00000169255), B3GNT2 (ENSG00000170340), B3GALT6 (ENSG00000176022), B3GNT4 (ENSG00000176383), B3GNT5 (ENSG00000176597), B3GNT8 (ENSG00000177191), B3GNT3 (ENSG00000179913), B3GALT5 (ENSG00000183778), B3GNT6 (ENSG00000198488), B3GALT9 (ENSG00000214654), B3GALT4 (ENSG00000235863), B3GNT9 (ENSG00000237172)

Protein

Protein identifiers

Beta-1,3-galactosyltransferase 1 — Q9Y5Z6 (reviewed: Q9Y5Z6)

Alternative names: UDP-galactose:beta-N-acetyl-glucosamine-beta-1,3-galactosyltransferase 1

All UniProt accessions (1): Q9Y5Z6

UniProt curated annotations — full annotation on UniProt →

Function. Beta-1,3-galactosyltransferase that transfers galactose from UDP-alpha-D-galactose to substrates with a terminal beta-N-acetylglucosamine (beta-GlcNAc) residue. Involved in the biosynthesis of the carbohydrate moieties of glycolipids and glycoproteins. Inactive towards substrates with terminal alpha-N-acetylglucosamine (alpha-GlcNAc) or alpha-N-acetylgalactosamine (alpha-GalNAc) residues.

Subcellular location. Golgi apparatus membrane.

Tissue specificity. Detected in brain and colon mucosa and to a lesser extent in colon adenocarcinoma cells.

Pathway. Protein modification; protein glycosylation.

Similarity. Belongs to the glycosyltransferase 31 family.

RefSeq proteins (1): NP_066191* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002659	Glyco_trans_31	Family
IPR029044	Nucleotide-diphossugar_trans	Homologous_superfamily

Pfam: PF01762

Enzyme classification (BRENDA):

• EC 2.4.1.134 — galactosylxylosylprotein 3-beta-galactosyltransferase (BRENDA: 6 organisms, 19 substrates, 0 inhibitors, 2 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

2 substrates with measured Km, best-characterized 2. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
PYRIDINE 3-O-BETA-GALACTOSIDE	100	1
UDPGALACTOSE	1.05	1

Catalyzed reactions (Rhea), 2 shown:

• a beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1)-Cer(d18:1(4E)) + UDP-alpha-D-galactose = a beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1’)-Cer(d18:1(4E)) + UDP + H(+) (RHEA:16045)
• an N-acetyl-beta-D-glucosaminyl derivative + UDP-alpha-D-galactose = a beta-D-galactosyl-(1->3)-N-acetyl-beta-D-glucosaminyl derivative + UDP + H(+) (RHEA:53432)

UniProt features (6 total): topological domain 2, glycosylation site 2, chain 1, transmembrane region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9Y5Z6-F1	89.11	0.80

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (2): 47, 151

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-9037629	Lewis blood group biosynthesis
R-HSA-1430728	Metabolism
R-HSA-71387	Metabolism of carbohydrates and carbohydrate derivatives
R-HSA-9033658	Blood group systems biosynthesis

MSigDB gene sets: 94 (showing top): GOBP_OLIGOSACCHARIDE_METABOLIC_PROCESS, GAUSSMANN_MLL_AF4_FUSION_TARGETS_C_UP, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, WEI_MYCN_TARGETS_WITH_E_BOX, GOBP_SPHINGOLIPID_METABOLIC_PROCESS, GOBP_AMIDE_METABOLIC_PROCESS, chr2q24, GOBP_CARBOHYDRATE_METABOLIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_OLIGOSACCHARIDE_BIOSYNTHETIC_PROCESS, GOBP_CERAMIDE_METABOLIC_PROCESS, GOBP_LIPOSACCHARIDE_METABOLIC_PROCESS, GOBP_MEMBRANE_LIPID_METABOLIC_PROCESS, GTCAGGA_MIR378, REACTOME_METABOLISM_OF_CARBOHYDRATES_AND_CARBOHYDRATE_DERIVATIVES

GO Biological Process (8): protein O-linked glycosylation (GO:0006493), glucosylceramide metabolic process (GO:0006678), oligosaccharide biosynthetic process (GO:0009312), obsolete protein glycosylation (GO:0006486), lipid metabolic process (GO:0006629), galactosylceramide biosynthetic process (GO:0006682), obsolete lipid glycosylation (GO:0030259), carbohydrate derivative biosynthetic process (GO:1901137)

GO Molecular Function (4): N-acetyl-beta-D-glucosaminide beta-(1,3)-galactosyltransferase activity (GO:0008499), transferase activity (GO:0016740), glycosyltransferase activity (GO:0016757), hexosyltransferase activity (GO:0016758)

GO Cellular Component (3): Golgi membrane (GO:0000139), membrane (GO:0016020), Golgi apparatus (GO:0005794)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Blood group systems biosynthesis	1
Metabolism	1
Metabolism of carbohydrates and carbohydrate derivatives	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
glycoprotein biosynthetic process	1
glycosylceramide metabolic process	1
oligosaccharide metabolic process	1
carbohydrate biosynthetic process	1
primary metabolic process	1
galactosylceramide metabolic process	1
glycosphingolipid biosynthetic process	1
galactolipid biosynthetic process	1
ceramide biosynthetic process	1
biosynthetic process	1
carbohydrate derivative metabolic process	1
UDP-galactosyltransferase activity	1
beta-1,3-galactosyltransferase activity	1
catalytic activity	1
transferase activity	1
glycosyltransferase activity	1
Golgi apparatus	1
bounding membrane of organelle	1
cellular anatomical structure	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

638 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
B3GALT1	C1GALT1	Q9NS00	877
B3GALT1	B4GALT1	P15291	847
B3GALT1	B4GALNT2	Q8NHY0	846
B3GALT1	A4GALT	Q9NPC4	833
B3GALT1	WDR46	O15213	763
B3GALT1	RPS18	P25232	633
B3GALT1	B4GALT2	O60909	515
B3GALT1	FUT6	P51993	505
B3GALT1	LALBA	P00709	492
B3GALT1	ST6GALNAC6	Q969X2	492
B3GALT1	FUT1	P19526	491
B3GALT1	B4GALT4	O60513	490
B3GALT1	ST3GAL3	Q11203	461
B3GALT1	A3GALT2	U3KPV4	454
B3GALT1	B4GALT5	O43286	438

IntAct

0 interactions, top by confidence:

BioGRID (3): SLC35A2 (Affinity Capture-Western), B3GALT1 (Protein-peptide), B3GALT1 (Affinity Capture-MS)

ESM2 similar proteins: A0A2C9JXL4, O43825, O54904, O54905, O75752, O93403, P79948, P79949, Q08BL3, Q0VC84, Q24342, Q5F3G7, Q5HZL5, Q5R5Y3, Q5RAL7, Q5XJP0, Q5YB40, Q66H69, Q6AY39, Q6DE15, Q6GNL1, Q6P3P5, Q6QMG1, Q76EC5, Q793U7, Q7JK24, Q7JK25, Q7JK26, Q7K237, Q7SYI5, Q7T3S5, Q864U6, Q864U8, Q8BGY6, Q8K0J2, Q8NFL0, Q920V1, Q99NB2, Q9BYG0, Q9JI67

Diamond homologs: A8MXE2, O43825, O54904, O54905, O75752, O88178, O96024, Q1RLK6, Q5HZL5, Q5JCS9, Q5R5Y3, Q5RAL7, Q66H69, Q6AY39, Q6DE15, Q6P3P5, Q793U7, Q7JK24, Q7JK25, Q7JK26, Q7T3S5, Q864U6, Q864U8, Q8BGY6, Q8R3I9, Q920V1, Q95US5, Q99NB2, Q9BYG0, Q9C0J1, Q9JI67, Q9MYM7, Q9N293, Q9N294, Q9N295, Q9Y2A9, Q9Y2C3, Q9Y5Z6, Q9Z0F0, Q3USF0

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

47 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	5
Likely pathogenic	1
Uncertain significance	35
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (6)

Variant ID	HGVS	Classification
144471	GRCh38/hg38 2q24.3(chr2:164920562-167536439)x3	Pathogenic
4070970	NM_020981.4(B3GALT1):c.402C>G (p.Ser134Arg)	Pathogenic
442396	GRCh37/hg19 2q24.3(chr2:164366067-169069454)x1	Pathogenic
442551	GRCh37/hg19 2q24.3(chr2:166374955-169671203)x1	Pathogenic
981210	GRCh37/hg19 2q24.2-31.3(chr2:163078055-182119617)x1	Pathogenic
493569	GRCh37/hg19 2q24.3-31.1(chr2:165173620-169779326)x1	Likely pathogenic

SpliceAI

0 predictions. Top by Δscore:

AlphaMissense

2178 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:167869319:C:A	R94S	1.000
2:167869319:C:G	R94G	1.000
2:167869320:G:C	R94P	1.000
2:167869332:G:C	R98T	1.000
2:167869332:G:T	R98I	1.000
2:167869333:A:C	R98S	1.000
2:167869333:A:T	R98S	1.000
2:167869455:A:T	D139V	1.000
2:167869494:T:C	L152P	1.000
2:167869503:A:T	K155I	1.000
2:167869504:A:C	K155N	1.000
2:167869504:A:T	K155N	1.000
2:167869523:T:A	W162R	1.000
2:167869523:T:C	W162R	1.000
2:167869540:T:G	C167W	1.000
2:167869568:G:C	D177H	1.000
2:167869569:A:C	D177A	1.000
2:167869569:A:T	D177V	1.000
2:167869575:A:C	D179A	1.000
2:167869575:A:G	D179G	1.000
2:167869575:A:T	D179V	1.000
2:167869652:G:C	G205R	1.000
2:167869653:G:A	G205D	1.000
2:167869696:G:C	K219N	1.000
2:167869696:G:T	K219N	1.000
2:167869697:T:A	W220R	1.000
2:167869697:T:C	W220R	1.000
2:167869699:G:C	W220C	1.000
2:167869699:G:T	W220C	1.000
2:167869742:T:C	F235L	1.000

dbSNP variants (sampled 300 via entrez): RS1000007542 (2:167684456 A>G), RS1000027781 (2:167533981 T>C), RS1000029332 (2:167291205 T>C), RS1000035139 (2:167419017 T>C), RS1000036628 (2:167718972 A>G), RS1000039764 (2:167696247 G>C,T), RS1000050715 (2:167531117 T>C), RS1000056231 (2:167490800 A>T), RS1000062283 (2:167725489 C>A,G), RS1000063779 (2:167378982 G>C,T), RS1000065490 (2:167689600 G>A,T), RS1000072949 (2:167570858 A>G), RS1000074030 (2:167767766 C>G), RS1000079684 (2:167419916 T>G), RS1000083104 (2:167844555 C>A,G,T)

Disease associations

OMIM: gene MIM:603093 | disease phenotypes: MIM:143890

GenCC curated gene-disease

Mondo (3): prostate cancer (MONDO:0008315), hypercholesterolemia, familial, 1 (MONDO:0007750), 2q24 microdeletion syndrome (MONDO:0015566)

Orphanet (3): Familial prostate cancer (Orphanet:1331), Homozygous familial hypercholesterolemia (Orphanet:391665), Developmental delay-language impairment-dopa responsive dystonia-parkinsonism syndrome due to 2q24 microdeletion (Orphanet:1617)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001762_577	Obesity-related traits	2.000000e-06
GCST006479_3	Diverticular disease	6.000000e-06
GCST006950_49	Feeling worry	9.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0004730	hormone measurement
EFO:0009959	diverticular disease
EFO:0009589	worry measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750
C538316	Chromosome 2, monosomy 2q24 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2321634 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

9 total (human), top 9 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases expression	2
aristolochic acid I	decreases expression	1
methyleugenol	decreases expression	1
CGP 52608	affects binding, increases reaction	1
(+)-JQ1 compound	increases expression	1
Benzo(a)pyrene	affects methylation, decreases methylation, increases methylation	1
Triclosan	decreases expression	1
Valproic Acid	increases expression	1
Okadaic Acid	increases expression	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2329327	Binding	Inhibition of human recombinant soluble His-tagged beta3-GalT1 expressed in insect cells using GlcNAcbeta-Bn as substrate at 0.5 mM after 1 hr in presence of phosphatidylcholine	Selective inhibition of glycosyltransferases by bivalent imidazolium salts. — Bioorg Med Chem

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer